Franco M. Muggia

ORCID: 0000-0003-0703-9146 · 5 papers in corpus
2017
Gynecologic Oncology ·doi:10.1016/j.ygyno.2017.08.004

PurposeWe examined disparities in prognosis between patients with ovarian clear cell carcinoma (OCCC) and serous epithelial ovarian cancer (SOC).MethodsWe reviewed data from FIGO stage I-IV epithelial ovarian cancer patients who participate…

2013
Ecancermedicalscience ·doi:10.3332/ecancer.2013.335

Gonadotropin-releasing hormone (GnRH) agonists are used for gonadal suppression in the treatment of breast and prostate cancers. In older men, their use has occasionally been associated with cardiovascular side effects such as supraventricu…

2009
Molecular cancer therapeutics ·doi:10.1158/1535-7163.mct-08-0731

This conference opened with Franco Muggia, host and principal organizer, thanking Joseph Landolph, co-Chair of the International Scientific Organizing Committee and its members (Franco Muggia, co-Chair, Max Costa, Steven Burakoff, Howard Ho…

article 2002

Background. Mullerian adenosarcoma is a rare pelvic malig- nancy that most commonly arises from the endometrium. These tumors are relatively insensitive to chemotherapy and radiation and are primarily treated by surgical resection. We repor…

article 2002
Gynecologic Oncology ·doi:10.1006/gyno.2002.6585

BackgroundMüllerianadenosarcoma is a rare pelvic malignancy that most commonly arises from the endometrium. These tumors are relatively insensitive to chemotherapy and radiation and are primarily treated by surgical resection. We report a c…